Wave Life Sciences Announces Positive Interim Phase 1 Data for WVE-007 in Obesity Trial

Wave Life Sciences Ltd.

Single 240 mg dose of WVE-007 reduced visceral fat by 14% (placebo-adjusted, p<0.05) at six months.
WVE-007 showed preservation of lean mass (+2%) and waist circumference reduction (-3%) at six months.
Phase 2a portion of INLIGHT in higher BMI (35-50 kg/m2) to initiate in 2Q 2026.
WVE-007 continues to be generally safe and well tolerated with no severe TEAEs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.